Endolytix Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $9.3M

  • Investors
  • 3

Endolytix General Information

Description

Developer of novel therapeutics designed to cure antibiotic infections. The company provides therapies that are effective in killing pathogenic bacteria, including multidrug-resistant bacteria, enabling the healthcare industry to address the most resistant antibiotic infections that are difficult to access and treat.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 48 Dunham Ridge
  • Suite 5850
  • Beverly, MA 01915
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 48 Dunham Ridge
  • Suite 5850
  • Beverly, MA 01915
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Endolytix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 07-Aug-2024 $9.3M Completed Generating Revenue
2. Accelerator/Incubator Completed Generating Revenue
1. Early Stage VC 26-Mar-2021 $12M $12M Completed Generating Revenue
To view Endolytix’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Endolytix Patents

Endolytix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024020533-A1 Immunogenic compositions for treating or preventing actinomycetia infections Inactive 22-Jul-2022
WO-2024020543-A2 Kits and methods for diagnosing and treating actinomycetia infections Inactive 22-Jul-2022
WO-2024020543-A3 Kits and methods for diagnosing and treating actinomycetia infections Inactive 22-Jul-2022
AU-2023265152-A1 Compositions and methods for the treatment of actinomycetia infections Pending 06-May-2022
EP-4518840-A2 Compositions and methods for the treatment of actinomycetia infections Inactive 06-May-2022 A61K38/47
To view Endolytix’s complete patent history, request access »

Endolytix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Endolytix Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Kineticos Life Sciences Management Venture Capital Minority
Morningside Group Venture Capital Minority
InnoVentures Lab Accelerator/Incubator
To view Endolytix’s complete investors history, request access »

Endolytix FAQs

  • When was Endolytix founded?

    Endolytix was founded in 2020.

  • Where is Endolytix headquartered?

    Endolytix is headquartered in Beverly, MA.

  • What is the size of Endolytix?

    Endolytix has 16 total employees.

  • What industry is Endolytix in?

    Endolytix’s primary industry is Drug Discovery.

  • Is Endolytix a private or public company?

    Endolytix is a Private company.

  • What is Endolytix’s current revenue?

    The current revenue for Endolytix is .

  • How much funding has Endolytix raised over time?

    Endolytix has raised $21.3M.

  • Who are Endolytix’s investors?

    Kineticos Life Sciences Management, Morningside Group, and InnoVentures Lab have invested in Endolytix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process